[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.75.176. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2009

Efficacy of Adalimumab in the Treatment of Generalized Granuloma Annulare in Monozygotic Twins Carrying the 8.1 Ancestral Haplotype

Arch Dermatol. 2009;145(5):610-611. doi:10.1001/archdermatol.2009.92

Granuloma annulare (GA) is a condition of unknown cause characterized by the appearance of cutaneous necrobiotic granuloma. Localized forms of GA are usually asymptomatic and self-limited, with spontaneous resolution occurring often within 2 years. However, disseminated GA (DGA) tends to be more chronic and pruritic and may last for decades.

Some investigations have shown that an overexpression of tumor necrosis factor α (TNF-α) by peripheral mononuclear lymphocytes and macrophages may play a role in the development of GA.1 Tumor necrosis factor α blocking agents such as etanercept and infliximab have helped resolve the disease in some cases.2,3 In others, however, no response or a worsening of the condition was reported.4 The reason for this varying response remains unknown.

First Page Preview View Large
First page PDF preview
First page PDF preview
×